Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B

By sjmartinez • April 2, 2024

Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. Antimicrob Agents Chemother. 2024 Apr 1:e0154523. doi: 10.1128/aac.01545-23. Epub ahead of print. PMID: 38557112.

Tags: combination therapy, Harbor UCLA, Ibrexafungerp, infection model, Infectious Diseases, liposomal amphotericin B, mouse, mucor, mucormycosis, posaconazole, Publications, Rhizopus

Serum extracellular vesicle RNA profiles in long COVID: insights from exercise-induced gene modulation

Abbasi A, Hansen N, Palade J, Paredes D, Meechoovet B, Van Keuren-Jensen K, Pirrotte P, Stringer WW. Serum extracellular vesicle RNA profiles in long COVID:[...]

Predictors of diffuse coronary artery calcium phenotype in adults aged ≥ 75: The Atherosclerosis Risk in Communities (ARIC) study

Gami A, Zou S, Dardari ZA, Dudum R, Mok Y, Budoff MJ, Lutsey PL, Howard CM, Couper D, Matsushita K, Blaha MJ. Predictors of diffuse[...]

Parasex generates highly recombinant progeny in Candida albicans with increased virulence

Fillinger RJ, Mishra A, Loza L, Sircaik S, Carriel CC, Mackey AI, Stratton TD, Filler SG, Selmecki AM, Bennett RJ, Anderson MZ. Parasex generates highly[...]